Business Description
TherapeuticsMD Inc
NAICS : 325412
SIC : 2834
ISIN : US88338N2062
Total Employee Number:
1Description
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.44 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -1.89 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -33.65 | |||||
Beneish M-Score | -2.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -67.3 | |||||
3-Year FCF Growth Rate | -39.6 | |||||
3-Year Book Growth Rate | -14.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.41 | |||||
9-Day RSI | 56.75 | |||||
14-Day RSI | 54.56 | |||||
3-1 Month Momentum % | -4.95 | |||||
6-1 Month Momentum % | 21.26 | |||||
12-1 Month Momentum % | 80.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.11 | |||||
Quick Ratio | 3.11 | |||||
Cash Ratio | 1.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | 4.18 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -111.66 | |||||
Net Margin % | 5.34 | |||||
EBITDA Margin % | -91.83 | |||||
FCF Margin % | 80.5 | |||||
OCF Margin % | 80.5 | |||||
ROE % | 0.66 | |||||
ROA % | 0.47 | |||||
ROIC % | -9.08 | |||||
3-Year ROIIC % | 43.36 | |||||
ROC (Joel Greenblatt) % | -77.4 | |||||
ROCE % | -12.82 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 112.03 | |||||
Forward PE Ratio | 8.32 | |||||
PE Ratio without NRI | 320.09 | |||||
PS Ratio | 7.76 | |||||
PB Ratio | 0.96 | |||||
Price-to-Tangible-Book | 1.11 | |||||
Price-to-Free-Cash-Flow | 9.67 | |||||
Price-to-Operating-Cash-Flow | 9.67 | |||||
EV-to-EBIT | -5.47 | |||||
EV-to-Forward-EBIT | 27.38 | |||||
EV-to-EBITDA | -7.58 | |||||
EV-to-Revenue | 6.96 | |||||
EV-to-Forward-Revenue | 0.92 | |||||
EV-to-FCF | 8.65 | |||||
Price-to-GF-Value | 1.08 | |||||
Price-to-Graham-Number | 4 | |||||
| Price-to-Net-Current-Asset-Value | 5.6 | |||||
Earnings Yield (Greenblatt) % | -18.28 | |||||
FCF Yield % | 10.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TXMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TherapeuticsMD Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.353 | ||
| EPS (TTM) ($) | 0.02 | ||
| Beta | 1.3066 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.18 | ||
| Volatility % | 60.81 | ||
| 14-Day RSI | 54.56 | ||
| 14-Day ATR ($) | 0.143577 | ||
| 20-Day SMA ($) | 2.04095 | ||
| 12-1 Month Momentum % | 80.34 | ||
| 52-Week Range ($) | 0.9811 - 2.95 | ||
| Shares Outstanding (Mil) | 11.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TherapeuticsMD Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TherapeuticsMD Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-15 08:00 | In 170 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 44 days | ||
| First quarter earnings results for 2026 | 2026-05-12 | 1.96 (+0.00%) | ||
| Annual report for 2025 | 2026-03-30 | 2.10 (-4.55%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 2.10 (-4.55%) | ||
| General meeting for 2025 | 2025-12-15 08:00 | 1.75 (-4.37%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.64 (+20.22%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 1.08 (+0.93%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 1.48 (+1.37%) |
Show
Entries
TherapeuticsMD Inc Frequently Asked Questions
What is TherapeuticsMD Inc(TXMD)'s stock price today?
The current price of TXMD is $2.24. The 52 week high of TXMD is $2.95 and 52 week low is $0.98.
When is next earnings date of TherapeuticsMD Inc(TXMD)?
The next earnings date of TherapeuticsMD Inc(TXMD) is 2026-08-12 Est..
Does TherapeuticsMD Inc(TXMD) pay dividends? If so, how much?
TherapeuticsMD Inc(TXMD) does not pay dividend.
Guru Commentaries on NAS:TXMD
No articles.
Press Release
Articles on TherapeuticsMD Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers